Chenqi Xu

20PUBLICATIONS
76CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityProteomics and intermolecular interactions (excl. medical proteomics)Psychopharmacology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 05, 2026
HMGCS1 drives cholesterol-dependent membrane repair and shields tumor cells from lymphocyte attack.

|Mar 03, 2026
Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.

Meggy Suarez-Carmona, Mareike Hampel, Xin-Wen Zhang

|Sep 10, 2025
Amplifying antigen-induced cellular responses with proximity labelling.

Shuojun Li, Yinghui Men, Zihan Wang

|Nov 11, 2024
Charge-based immunoreceptor signalling in health and disease.

Xiaoshan Shi, Xing He, Chenqi Xu

|Nov 02, 2024
Publisher Correction: Cytoplasmic FBXO38 mediates PD-1 degradation.

Xiwei Liu, Xiangbo Meng, Zuomiao Lin

|Sep 18, 2024
Cytoplasmic FBXO38 mediates PD-1 degradation.

Xiwei Liu, Xiangbo Meng, Zuomiao Lin

Pageof 4

Frequent Collaborators

3 joint publications

Guangchuan Wang

2 joint publications

Zhengjiang Zhu

2 joint publications

Shao-Cong Sun

2 joint publications

Penghui Zhou